Orforglipron linked to weight loss in adults 65 and older in ATTAIN analysis

A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials found that adults aged 65 and older who took once-daily oral orforglipron lost more weight than those who took placebo at 72 weeks, with results similar to younger participants ^[1]. The analysis was published in Obesity Pillars in September 2026 ^[1].

Orforglipron is described in the paper as a small-molecule, non-peptide oral GLP-1 receptor agonist, meaning a pill rather than an injection, being studied in Phase 3 trials ^[1]. ATTAIN-1 enrolled people with obesity, and ATTAIN-2 enrolled people with obesity and type 2 diabetes ^[1]. In both trials, participants took orforglipron or placebo once a day alongside a healthy diet and physical activity ^[1].

The older-age group was small relative to the full trials. Across the two studies, 616 randomized participants were 65 or older, and 613 of them received treatment: 118 took orforglipron 5.5 mg, 135 took 9 mg, 146 took 17.2 mg, and 214 took placebo ^[1]. The main measure was percent change in body weight from the start of the study to Week 72 ^[1].

Among older participants in ATTAIN-1, weight fell by 7.9% (95% CI: −10.0 to −5.9) on 5.5 mg, 11.3% (−13.4 to −9.3) on 9 mg, and 13.0% (−15.7 to −10.4) on 17.2 mg, compared with 1.6% (−3.2 to 0.1) on placebo. All comparisons against placebo had p values below 0.001 ^[1].

Among older participants in ATTAIN-2, the changes were 7.5% (−9.1 to −5.9), 8.3% (−9.7 to −6.8), and 12.2% (−13.9 to −10.6) for the three orforglipron doses, versus 2.3% (−3.1 to −1.4) for placebo, also all p < 0.001 ^[1].

The paper states that comparable findings were observed in participants younger than 65 ^[1]. A highlight in the article also says older participants had "clinically meaningful reductions in body weight and HbA1c" consistent with younger participants, but the abstract does not give HbA1c figures ^[1].

Gastrointestinal adverse events were the most common with orforglipron and were generally mild to moderate in severity, according to the paper ^[1]. The authors report that safety findings were generally consistent across age groups and with the overall results from ATTAIN-1 and ATTAIN-2 ^[1].

The paper frames the analysis around a practical gap: it says fasting requirements for some oral therapies and needle avoidance may limit weight-management options for adults 65 and older, and that limited studies exist on incretin-based medications in older adults with obesity ^[1]. The authors describe the work as a post hoc subgroup analysis, meaning the age groups were drawn from two larger trials rather than from a trial designed specifically around people 65 and older ^[1]. Whether orforglipron carries food or fluid restrictions is not addressed in the analysis ^[1].

Why it matters for patients

Older adults are a group where the evidence base for this class of drugs has been thin, and this analysis provides age-specific weight numbers rather than extrapolating from younger participants ^[1]. For a patient over 65 with obesity, with or without type 2 diabetes, that is more directly relevant information than results from a mostly younger study population ^[1].

The limits matter too. The analysis was not designed to answer every question that comes up with weight-loss drugs in older adults. It does not report muscle mass, bone density or fracture outcomes, so it cannot say whether the weight lost included lean tissue ^[1]. It also does not report whether the older participants had different rates of falls, hospitalizations or other events ^[1].

Because the older subgroup totaled 613 treated participants split across three doses and a placebo group, the numbers for any single dose come from roughly 118 to 146 people ^[1]. Smaller groups produce less precise estimates, which is why the paper reports confidence intervals around each result ^[1].

What is not yet known

Regulatory status is not addressed in the analysis ^[1]. ATTAIN-1 is registered as NCT05869903 and ATTAIN-2 as NCT05872620, but the published analysis gives no dates for further studies or submissions ^[1]. Whether a future trial will be built specifically around adults 65 and older, and whether it would measure muscle, bone or fracture outcomes, has not been reported ^[1].